MCID: SRC014
MIFTS: 68

Sarcoma

Categories: Cancer diseases, Bone diseases

Aliases & Classifications for Sarcoma

MalaCards integrated aliases for Sarcoma:

Name: Sarcoma 12 28 51 69 14
Connective and Soft Tissue Neoplasm 12
Tumor of Soft Tissue and Skeleton 12
Sarcoma - Category 69

Classifications:



External Ids:

Disease Ontology 12 DOID:1115
ICD10 32 C49
ICD9CM 34 171 171.9
SNOMED-CT 64 187985009 93765001

Summaries for Sarcoma

Disease Ontology : 12 A cell type cancer that has material basis in abnormally proliferating cells derives from embryonic mesoderm.

MalaCards based summary : Sarcoma, also known as connective and soft tissue neoplasm, is related to sarcoma, synovial and esophagus sarcoma. An important gene associated with Sarcoma is SRC (SRC Proto-Oncogene, Non-Receptor Tyrosine Kinase), and among its related pathways/superpathways are GPCR Pathway and Developmental Biology. The drugs Doxil and Fusilev have been mentioned in the context of this disorder. Affiliated tissues include bone, myeloid and lung, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Sarcoma

Diseases related to Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 962)
# Related Disease Score Top Affiliating Genes
1 sarcoma, synovial 34.2 KIT SS18 SSX1 SSX2 SSX3
2 esophagus sarcoma 33.9 CREB3L2 KIT
3 spindle cell synovial sarcoma 33.7 KIT SS18 SSX1 SSX2
4 ewing sarcoma 33.6 EWSR1 FLI1 JUN KIT PDGFB SS18
5 bone ewing's sarcoma 33.3 EWSR1 FES PDGFB
6 skin sarcoma 32.9 CREB3L2 EWSR1 PDGFB
7 muscle cancer 31.8 ASPSCR1 CREB3L2 EWSR1 KIT
8 synovium cancer 31.6 CREB3L2 EWSR1 SS18 SSX1 SSX3
9 leukemia, acute myeloid 30.7 HRAS JUN KIT KRAS SRC
10 chondrosarcoma, extraskeletal myxoid 30.4 CREB3L2 EWSR1 SS18
11 adenocarcinoma 30.4 BRAF HRAS KIT KRAS RB1
12 leukemia, chronic myeloid 30.2 HRAS KIT LYN SRC
13 neurofibromatosis, type iv, of riccardi 30.2 HRAS KIT KRAS
14 pulmonic stenosis 29.9 BRAF HRAS KRAS
15 lung adenoid cystic carcinoma 29.8 HRAS KIT KRAS
16 spitz nevus 29.6 BRAF HRAS
17 glioblastoma 29.6 BRAF HRAS PDGFB RB1
18 glioblastoma multiforme 29.1 BRAF HRAS PDGFB RB1
19 connective tissue cancer 28.8 CREB3L2 EWSR1 KIT PDGFB SS18 SSX1
20 kaposi sarcoma 12.6
21 follicular dendritic cell sarcoma 12.3
22 alveolar soft part sarcoma 12.3
23 myeloid sarcoma 12.3
24 endometrial stromal sarcoma 12.3
25 epithelioid sarcoma 12.3
26 langerhans cell sarcoma 12.3
27 soft tissue sarcoma 12.3
28 osteogenic sarcoma 12.2
29 clear cell sarcoma 12.2
30 kidney clear cell sarcoma 12.2
31 undifferentiated pleomorphic sarcoma 12.2
32 spindle cell sarcoma 12.2
33 paraganglioma and gastric stromal sarcoma 12.2
34 uterine sarcoma 12.1
35 prostate stromal sarcoma 12.1
36 retroperitoneal sarcoma 12.1
37 bladder sarcoma 12.1
38 heart sarcoma 12.1
39 liver sarcoma 12.1
40 small intestinal sarcoma 12.1
41 gallbladder sarcoma 12.0
42 interdigitating dendritic cell sarcoma 12.0
43 colon kaposi sarcoma 12.0
44 reticulum cell sarcoma 12.0
45 histiocytic sarcoma 12.0
46 penis sarcoma 12.0
47 mediastinum sarcoma 12.0
48 bile duct sarcoma 12.0
49 vulvar alveolar soft part sarcoma 11.9
50 mediastinum synovial sarcoma 11.9

Graphical network of the top 20 diseases related to Sarcoma:



Diseases related to Sarcoma

Symptoms & Phenotypes for Sarcoma

GenomeRNAi Phenotypes related to Sarcoma according to GeneCards Suite gene sharing:

25 (show all 19)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.53 HRAS KRAS BRAF
2 Decreased viability GR00106-A-0 10.53 KRAS
3 Decreased viability GR00221-A-1 10.53 HRAS KRAS KIT
4 Decreased viability GR00221-A-2 10.53 PDGFB YES1 HRAS KRAS JUN
5 Decreased viability GR00221-A-3 10.53 PDGFB YES1 HRAS LYN JUN
6 Decreased viability GR00221-A-4 10.53 YES1 BRAF
7 Decreased viability GR00240-S-1 10.53 PDGFB
8 Decreased viability GR00301-A 10.53 SRC KRAS KIT BRAF
9 Decreased viability GR00342-S-1 10.53 LYN
10 Decreased viability GR00342-S-2 10.53 LYN
11 Decreased viability GR00342-S-3 10.53 LYN
12 Decreased viability GR00381-A-1 10.53 KRAS BRAF
13 Decreased substrate adherent cell growth GR00193-A-1 10.34 PDGFB KIT FES
14 Decreased substrate adherent cell growth GR00193-A-2 10.34 YES1 PDGFB KIT FES
15 Decreased substrate adherent cell growth GR00193-A-3 10.34 YES1 PDGFB BRAF
16 Decreased substrate adherent cell growth GR00193-A-4 10.34 YES1 PDGFB KIT BRAF
17 Decreased cell migration GR00055-A-1 9.8 YES1 LYN BRAF KRAS FES HRAS
18 Decreased viability in HMC1.1 cells GR00105-A-0 9.13 SRC LYN KIT
19 Increased cell migration GR00055-A-3 8.92 KRAS HRAS LYN BRAF

MGI Mouse Phenotypes related to Sarcoma:

43 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.34 KRAS KIT JUN CREB3L2 HRAS FES
2 mortality/aging MP:0010768 10.28 KRAS KIT LYN JUN CREB3L2 HRAS
3 cardiovascular system MP:0005385 10.27 JUN KRAS KIT BRAF FLI1 HRAS
4 hematopoietic system MP:0005397 10.25 JUN KRAS KIT BRAF FLI1 FES
5 immune system MP:0005387 10.24 JUN KRAS KIT BRAF FLI1 FES
6 integument MP:0010771 10.22 KIT LYN JUN KRAS HRAS FES
7 embryo MP:0005380 10.2 KRAS KIT JUN FLI1 BRAF RB1
8 endocrine/exocrine gland MP:0005379 10.19 JUN KRAS HRAS KIT BRAF FLI1
9 nervous system MP:0003631 10.18 KIT LYN JUN KRAS HRAS FES
10 craniofacial MP:0005382 10.17 KRAS KIT CREB3L2 HRAS FES BRAF
11 digestive/alimentary MP:0005381 10.16 KRAS KIT CREB3L2 HRAS FES BRAF
12 liver/biliary system MP:0005370 10.11 KIT LYN JUN KRAS FES BRAF
13 neoplasm MP:0002006 10.01 KRAS KIT HRAS FES BRAF FLI1
14 renal/urinary system MP:0005367 9.86 KRAS KIT HRAS BRAF RB1 LYN
15 respiratory system MP:0005388 9.85 KIT LYN JUN KRAS HRAS BRAF
16 pigmentation MP:0001186 9.8 KRAS KIT BRAF PDGFB SRC RB1
17 skeleton MP:0005390 9.61 JUN KRAS HRAS KIT BRAF CREB3L2
18 vision/eye MP:0005391 9.23 JUN KRAS KIT BRAF FES RB1

Drugs & Therapeutics for Sarcoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Doxil 17 45 DOXORUBICIN HYDROCHLORIDE Alza June 1999
2
Fusilev 17 LEVOLEUCOVORIN CALCIUM Spectrum Pharmaceuticals March of 2008
3
Intron A 17 45 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
4
Taxol 17 45 PACLITAXEL Bristol-Myers Squibb August 1997
5
Votrient 17 45 PAZOPANIB HYDROCHLORIDE GlaxoSmithKline April 2012/ October of 2009

Drugs for Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 598)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
2
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
3
Bleomycin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 11056-06-7 5360373
4
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
5
Efavirenz Approved, Investigational Phase 4,Phase 3 154598-52-4 64139
6
Ritonavir Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 155213-67-5 392622
7
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 216974-75-3
8
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
9
Lamivudine Approved, Investigational Phase 4,Phase 2,Phase 3 134678-17-4 60825
10
Nevirapine Approved Phase 4,Phase 3 129618-40-2 4463
11
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
12
Emtricitabine Approved, Investigational Phase 4,Phase 3 143491-57-0 60877
13
Lopinavir Approved Phase 4,Phase 2,Phase 3 192725-17-0 92727
14
Capecitabine Approved, Investigational Phase 4,Phase 2,Phase 1 154361-50-9 60953
15
Aspirin Approved, Vet_approved Phase 4,Phase 2 50-78-2 2244
16
Dalteparin Approved Phase 4,Phase 1 9005-49-6
17
Heparin Approved, Investigational Phase 4,Phase 1 9005-49-6 46507594 772
18
Ethiodized oil Approved, Investigational Phase 4 8008-53-5
19
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
20 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
21 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
22 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
23 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
25 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
26 Vaccines Phase 4,Phase 1,Phase 2
27 Anti-HIV Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
28 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1
30 Anti-Retroviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
31 Antiviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
32 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
33 HIV Protease Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
34
protease inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
35 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
36 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
37 Antimetabolites, Antineoplastic Phase 4,Phase 2,Phase 3,Phase 1
38 Antibodies Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
39 Antibodies, Monoclonal Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
40 Immunoglobulins Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
41 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
42 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
43 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
44 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1
45 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
46 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
47 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 3,Phase 2,Phase 1
48 Reverse Transcriptase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
49 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3
50 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 2,Phase 3

Interventional clinical trials:

(show top 50) (show all 1706)

# Name Status NCT ID Phase Drugs
1 EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children Unknown status NCT00339118 Phase 4 doxorubicin, cytoxan
2 Optimizing Influenza Vaccination in Surgical Oncology Patients Unknown status NCT01698177 Phase 4
3 HIV/AIDS Kaposis Sarcoma: Comparison of Response to HAART vs HAART Plus CXT Completed NCT00380770 Phase 4 Generic HAART Triomune : d4T, 3TC, NVP;Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV
4 Anti-Retrovirals for Kaposi's Sarcoma Completed NCT00444379 Phase 4 Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir
5 OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum. Completed NCT00577031 Phase 4 bevacizumab [Avastin];Oxaliplatin;Xeloda
6 Physical Characteristics of Retrieved Massive Allografts Completed NCT00160758 Phase 4
7 HLA Sensitization Following Major Cortical Allograft Bone Procedures Completed NCT00160719 Phase 4
8 Evaluation of Hyperbaric Oxygen Therapy on Wound Healing Following Management of Soft Tissue Sarcoma With Neo-Adjuvant Radiation and Surgical Resection Recruiting NCT03144206 Phase 4 Hyperbaric oxygen
9 Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer Recruiting NCT02301962 Phase 4 Panitumumab
10 Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma Recruiting NCT01669369 Phase 4 Lithium Carbonate;Placebo
11 Evaluation of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization. Recruiting NCT02625389 Phase 4 Lipiodol® Ultra Fluid with surgical glues
12 Stereotactic Body Radiotherapy for Head and Neck Tumors Active, not recruiting NCT01344356 Phase 4
13 Low Molecular Weight Heparin (LMWH) vs Aspirin for Venous Thromboembolism (VTE) Prophylaxis in Orthopaedic Oncology Not yet recruiting NCT03244020 Phase 4 Aspirin 325mg;Enoxaparin 40Mg/0.4mL Prefilled Syringe
14 The Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas Unknown status NCT00162721 Phase 3 doxorubicin, ifosfamide, cisplatin
15 Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma Unknown status NCT00002516 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;mesna;vincristine sulfate
16 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
17 An Adequate Cost Effective Follow Up Protocol For Bone & Soft Tissue Sarcomas - A Prospective Randomized Trial Unknown status NCT00384735 Phase 3
18 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma Unknown status NCT00020566 Phase 3 busulfan;doxorubicin hydrochloride;etoposide;ifosfamide;melphalan;vincristine sulfate
19 A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma Unknown status NCT00002318 Phase 3 Doxorubicin hydrochloride (liposomal);Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride
20 Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma Unknown status NCT00379457 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate;vinorelbine tartrate
21 TB-IRIS NSAID Cox-2 Inhibitor Prevention Trial Unknown status NCT02060006 Phase 3 Meloxicam 7.5mg daily for 8 weeks
22 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
23 Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumor Unknown status NCT00685828 Phase 3 imatinib mesylate
24 Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor Unknown status NCT00103168 Phase 3 imatinib mesylate
25 A Clinical Trial on Efficacy and Safety for Lobaplatin and Gemcitabine in Combination With Docetaxel in the Second-line Treatments on Advanced Osteosarcoma Unknown status NCT02099396 Phase 2, Phase 3 Docetaxel+lobaplatin;Gemcitabine+lobaplatin
26 Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma Unknown status NCT00691236 Phase 2, Phase 3 Zoledronic acid;Standard chemotherapy
27 Study Comparing the Safety and Effectiveness of Magnetic Resonance Guided Focused Ultrasound (MRgFUS) and External Beam Radiation (EBRT) for Treatment of Metastatic Bone Tumors and Multiple Myeloma Unknown status NCT01091883 Phase 3
28 A Prospective Randomized Trial of Pre-Operative IMRT+Surgery Versus Surgery Alone For Primary Retroperitoneal Sarcoma Completed NCT00131898 Phase 3
29 A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma Completed NCT01440088 Phase 3 TH-302 in Combination with Doxorubicin;Doxorubicin
30 Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma Completed NCT00142571 Phase 3 Gemcitabine;Docetaxel
31 Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor Completed NCT00006734 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
32 Doxorubicin in Treating Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00002985 Phase 3 daunorubicin hydrochloride;pegylated liposomal doxorubicin hydrochloride
33 Phase 3 Study to Treat Patients With Soft Tissue Sarcomas Completed NCT02049905 Phase 3 Aldoxorubicin;Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)
34 Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy Completed NCT00753688 Phase 3 PAZOPANIB;Placebo
35 An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS) Completed NCT00796120 Phase 3 Trabectedin;Doxorubicin;Ifosfamide
36 Observation Versus Post-surgery Radiotherapy After Complete Exeresis in Soft Tissues Members Sarcoma Completed NCT00870701 Phase 3
37 Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma Completed NCT01168791 Phase 3 doxorubicin in combination with palifosfamide-tris;doxorubicin in combination with placebo
38 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
39 Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma Completed NCT01327885 Phase 3 Eribulin mesylate 1.4 mg/m^2 intravenous;Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV
40 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
41 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
42 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
43 A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in Zimbabwe Completed NCT00834457 Phase 2, Phase 3 abacavir/3TC/zidovudine;abacavir /3TC plus ritonavir boosted lopinavir
44 Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6) Completed NCT00538239 Phase 3 ridaforolimus;Placebo
45 Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma Completed NCT00003350 Phase 3 paclitaxel;pegylated liposomal doxorubicin hydrochloride
46 A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's Sarcoma Completed NCT00002319 Phase 3 Doxorubicin hydrochloride (liposomal)
47 Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma. Completed NCT00002147 Phase 3 Doxorubicin hydrochloride (liposomal)
48 Safety and Effectiveness of an Experimental Drug, IM862, in Treating Kaposi's Sarcoma in AIDS Patients Completed NCT00002445 Phase 3 IM862
49 A Randomized Study of the Effect of Adjuvant Chemotherapy With Doxorubicin and Ifosfamide With Mesna in the Treatment of High-Grade Adult Extremity Soft Tissue Sarcoma Completed NCT00001300 Phase 3 doxorubicin;ifosfamide;mesna
50 Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma Completed NCT00002105 Phase 3 Doxorubicin hydrochloride (liposomal);Bleomycin sulfate;Vincristine sulfate

Search NIH Clinical Center for Sarcoma

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Genetic Tests for Sarcoma

Genetic tests related to Sarcoma:

# Genetic test Affiliating Genes
1 Sarcoma 28

Anatomical Context for Sarcoma

MalaCards organs/tissues related to Sarcoma:

38
Bone, Myeloid, Lung, Kidney, Liver, T Cells, Uterus

Publications for Sarcoma

Articles related to Sarcoma:

(show top 50) (show all 9553)
# Title Authors Year
1
Case of classic Kaposi sarcoma of the penis successfully treated with radiotherapy. ( 29341256 )
2018
2
Retroperitoneal follicular dendritic cell sarcoma in a young woman: Diagnosis and treatment challenges. ( 29395417 )
2018
3
Near-infrared intraoperative imaging during resection of an anterior mediastinal soft tissue sarcoma. ( 29387401 )
2018
4
Rubbery purple and red lesions in the GI tract: A Case of GI tract Kaposi Sarcoma. ( 29306041 )
2018
5
A remarkable response to pazopanib, despite recurrent liver toxicity, in a patient with a high grade endometrial stromal sarcoma, a case report. ( 29357824 )
2018
6
Synovial sarcoma mimicking a thoracic dumbell schwannoma- a case report. ( 29446979 )
2018
7
Role of Positron Emission Tomography Imaging in Myeloid Sarcoma. ( 29430131 )
2018
8
Treatment of Uterine Sarcoma with rAd-p53 (Gendicine) Followed by Chemotherapy: Clinical Study of TP53 Gene Therapy. ( 29281902 )
2018
9
Tumor suppressive ZBTB4 inhibits cell growth by regulating cell cycle progression and apoptosis in Ewing sarcoma. ( 29425745 )
2018
10
SN-38 Conjugated Gold Nanoparticles Activated by Ewing Sarcoma Specific mRNAs Exhibit In Vitro and In Vivo Efficacy. ( 29412642 )
2018
11
Biology and Management of Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, and Malignant Peripheral Nerve Sheath Tumors: State of the Art and Perspectives. ( 29220302 )
2018
12
Detection of prognostically relevant mutations and translocations in myeloid sarcoma by next generation sequencing. ( 28633614 )
2018
13
Isolated Pancreatic Myeloid Sarcoma Associated with t(8;21)/RUNX1-RUNX1T1 Rearrangement. ( 29151502 )
2018
14
Characterizing the potency and impact of carbon ion therapy in a primary mouse model of soft tissue sarcoma. ( 29437879 )
2018
15
The Ewing sarcoma secretome and its response to activation of Wnt/beta-catenin signaling. ( 29386236 )
2018
16
Management of metastatic retroperitoneal sarcoma: a consensus approach from the Transatlantic Retroperitoneal Sarcoma Working Group (TARPSWG). ( 29432564 )
2018
17
PD-1 blockade with nivolumab in endemic Kaposi sarcoma. ( 29324995 )
2018
18
Validation of a hypoxia related gene signature in multiple soft tissue sarcoma cohorts. ( 29423096 )
2018
19
Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas. ( 28868758 )
2018
20
Detection of circulating tumor cells in liquid biopsy from Ewing sarcoma patients. ( 29386915 )
2018
21
Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center retrospective study. ( 29185261 )
2018
22
Planning for Bone Excision in Ewing Sarcoma: Post-Chemotherapy MRI More Accurate Than Pre-Chemotherapy MRI Assessment. ( 29298256 )
2018
23
Sinusoidal obstruction syndrome/veno-occlusive disease after high-dose intravenous busulfan/melphalan conditioning therapy in high-risk Ewing Sarcoma. ( 29335623 )
2018
24
Clofarabine inhibits Ewing sarcoma growth through a novel molecular mechanism involving direct binding to CD99. ( 29382926 )
2018
25
Age of Infection with Kaposi Sarcoma Associated Herpesvirus and Subsequent Antibody Values Among Children in Uganda. ( 29369149 )
2018
26
EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma. ( 29358035 )
2018
27
Olaratumab in soft tissue sarcoma - Current status and future perspectives. ( 29413687 )
2018
28
Ring a ring o'roses, a patient with Kaposi's? Pazopanib, pazopanib, it might go away. Mediterranean (classic) Kaposi sarcoma responds to the tyrosine kinase inhibitor pazopanib after multiple lines of standard therapy. ( 29282751 )
2018
29
Alveolar Soft Part Sarcoma Presenting as Hypervascular Adrenal Metastasis. ( 29398970 )
2018
30
Treatment of Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease. ( 29157621 )
2018
31
Histiocytic sarcoma with bladder involvement: Case report and literature review. ( 29290317 )
2018
32
Dysregulated mitogen-activated protein kinase signalling as an oncogenic basis for clear cell sarcoma of the kidney. ( 29243812 )
2018
33
Chest wall resection and reconstruction for Rosai-Dorfman disease masquerading as a chest wall sarcoma. ( 29181991 )
2018
34
Kaposi sarcoma in an immunosuppressed young woman. ( 29398005 )
2018
35
Utility of Clinical Parameters and Multiparametric MRI as Predictive Factors for Differentiating Uterine Sarcoma From Atypical Leiomyoma. ( 29422425 )
2018
36
Correction: Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma. ( 29339354 )
2018
37
As-Needed versus Immediate Etoposide Chemotherapy in Combination with Antiretroviral Therapy for Mild or Moderate AIDS-associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial. ( 29365083 )
2018
38
F-18 FDG PET/CT in pulmonary artery sarcoma: clinical vignette. ( 29442347 )
2018
39
Radiation-related soft tissue sarcoma in a veterinary technician. ( 29398573 )
2018
40
Does an Algorithmic Approach to Using Brachytherapy and External Beam Radiation Result in Good Function, Local Control Rates, and Low Morbidity in Patients With Extremity Soft Tissue Sarcoma? ( 29443850 )
2018
41
Clinical Characteristics Differentiating Uterine Sarcoma and Fibroids. ( 29398899 )
2018
42
Prognostic value and functional role of ROCK2 in pediatric Ewing sarcoma. ( 29434937 )
2018
43
Immunohistochemical Expression of Different Subtypes of Cytokeratins by Endometrial Stromal Sarcoma. ( 29406332 )
2018
44
Reducing the spread of occult uterine sarcoma at the time of minimally invasive gynecologic surgery. ( 29128980 )
2018
45
Technological Advances, Biologic Rationales, and the Associated Success of Chemotherapy With Hyperthermia in Improved Outcomes in Patients With Sarcoma. ( 29450459 )
2018
46
Surgical management of esophageal sarcoma: a multicenter European experience. ( 29444281 )
2018
47
Acral Myxoinflammatory Fibroblastic Sarcoma Simulating Rheumatoid Bursitis - Diffusion-weighted Imaging. ( 29366969 )
2018
48
Establishment and proteomic characterization of a novel cell line, NCC-UPS2-C1, derived from a patient with undifferentiated pleomorphic sarcoma. ( 29359268 )
2018
49
Extracellular vesicle-encapsulated microRNA-761 enhances pazopanib resistance in synovial sarcoma. ( 29191657 )
2018
50
Individualized doxorubicin sensitivity testing of undifferentiated soft tissue sarcoma (USTS) in a patient-derived orthotopic xenograft (PDOX) model demonstrates large differences between patients. ( 29384032 )
2018

Variations for Sarcoma

ClinVar genetic disease variations for Sarcoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
2 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091

Expression for Sarcoma

Search GEO for disease gene expression data for Sarcoma.

Pathways for Sarcoma

Pathways related to Sarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 110)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.81 BRAF HRAS JUN KIT KRAS LYN
2
Show member pathways
13.57 BRAF FES HRAS JUN KIT KRAS
3
Show member pathways
13.45 BRAF HRAS KIT KRAS LYN PDGFB
4
Show member pathways
13.39 HRAS JUN KIT KRAS PDGFB SRC
5
Show member pathways
13.37 BRAF HRAS JUN KIT KRAS PDGFB
6
Show member pathways
13.3 BRAF FES HRAS JUN KRAS LYN
7
Show member pathways
13.16 BRAF HRAS KIT KRAS LYN PDGFB
8
Show member pathways
13.14 HRAS JUN KIT KRAS LYN PDGFB
9
Show member pathways
13.07 CREB3L2 HRAS KIT KRAS PDGFB RB1
10
Show member pathways
13.03 BRAF CREB3L2 HRAS JUN KIT KRAS
11
Show member pathways
13.01 HRAS JUN KRAS LYN PDGFB SRC
12
Show member pathways
12.98 BRAF HRAS JUN KRAS LYN SRC
13
Show member pathways
12.98 BRAF HRAS JUN KRAS PDGFB RB1
14
Show member pathways
12.92 BRAF CREB3L2 HRAS KRAS SRC YES1
15
Show member pathways
12.9 BRAF HRAS JUN KIT KRAS LYN
16 12.89 BRAF HRAS JUN KIT KRAS PDGFB
17
Show member pathways
12.88 BRAF HRAS JUN KRAS SRC
18
Show member pathways
12.87 BRAF HRAS JUN KIT KRAS RB1
19 12.86 BRAF HRAS JUN KIT KRAS PDGFB
20
Show member pathways
12.82 BRAF HRAS KIT KRAS PDGFB SRC
21
Show member pathways
12.82 BRAF CREB3L2 HRAS JUN KRAS SRC
22
Show member pathways
12.81 HRAS KIT KRAS LYN PDGFB SRC
23
Show member pathways
12.8 BRAF HRAS JUN KRAS SRC
24
Show member pathways
12.75 BRAF HRAS JUN KRAS PDGFB RB1
25 12.71 BRAF HRAS KRAS PDGFB SRC
26
Show member pathways
12.68 FES HRAS KRAS PDGFB SRC
27
Show member pathways
12.68 HRAS JUN KRAS LYN SRC
28
Show member pathways
12.59 BRAF HRAS JUN KRAS SRC
29
Show member pathways
12.58 BRAF CREB3L2 HRAS JUN KRAS RB1
30 12.53 HRAS JUN KRAS PDGFB RB1
31
Show member pathways
12.51 BRAF HRAS JUN KRAS PDGFB SRC
32
Show member pathways
12.5 HRAS KRAS LYN SRC
33
Show member pathways
12.5 HRAS JUN KIT KRAS PDGFB
34
Show member pathways
12.49 HRAS KRAS RB1 SRC
35
Show member pathways
12.48 BRAF HRAS JUN KRAS LYN
36
Show member pathways
12.46 CREB3L2 HRAS KIT KRAS SRC
37
Show member pathways
12.45 BRAF HRAS JUN SRC
38
Show member pathways
12.44 HRAS JUN KRAS SRC
39
Show member pathways
12.42 BRAF HRAS JUN KRAS
40
Show member pathways
12.42 BRAF HRAS JUN KRAS SRC YES1
41
Show member pathways
12.4 HRAS KRAS SRC YES1
42
Show member pathways
12.4 CREB3L2 HRAS JUN KRAS LYN
43 12.38 BRAF HRAS KRAS SRC
44
Show member pathways
12.38 BRAF HRAS KRAS SRC
45
Show member pathways
12.36 BRAF HRAS KRAS SRC
46
Show member pathways
12.36 BRAF HRAS JUN KRAS SRC
47
Show member pathways
12.34 BRAF HRAS JUN SRC YES1
48
Show member pathways
12.33 HRAS KRAS LYN SRC YES1
49 12.31 FES HRAS KRAS SRC
50
Show member pathways
12.29 HRAS JUN KRAS SRC

GO Terms for Sarcoma

Cellular components related to Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extrinsic component of cytoplasmic side of plasma membrane GO:0031234 9.02 FES KRAS LYN SRC YES1

Biological processes related to Sarcoma according to GeneCards Suite gene sharing:

(show all 39)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.99 BRAF HRAS KIT KRAS PDGFB SRC
2 MAPK cascade GO:0000165 9.95 BRAF HRAS KIT KRAS PDGFB
3 positive regulation of cell migration GO:0030335 9.94 HRAS KIT LYN PDGFB
4 Fc-epsilon receptor signaling pathway GO:0038095 9.93 HRAS JUN KRAS LYN
5 leukocyte migration GO:0050900 9.93 HRAS KRAS LYN SRC YES1
6 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.89 BRAF HRAS JUN PDGFB SRC
7 negative regulation of neuron apoptotic process GO:0043524 9.88 BRAF HRAS JUN KRAS
8 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.86 HRAS KRAS LYN SRC
9 transforming growth factor beta receptor signaling pathway GO:0007179 9.85 JUN PDGFB SRC
10 positive regulation of MAPK cascade GO:0043410 9.85 HRAS KIT PDGFB
11 hemopoiesis GO:0030097 9.84 KIT LYN PDGFB
12 T cell costimulation GO:0031295 9.83 LYN SRC YES1
13 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.83 LYN PDGFB SRC YES1
14 protein autophosphorylation GO:0046777 9.83 FES KIT LYN SRC YES1
15 negative regulation of nucleic acid-templated transcription GO:1903507 9.8 SSX1 SSX2 SSX3
16 regulation of cell proliferation GO:0042127 9.8 BRAF FES JUN KIT SRC YES1
17 visual learning GO:0008542 9.79 BRAF KIT KRAS
18 positive regulation of DNA replication GO:0045740 9.77 HRAS JUN PDGFB
19 Ras protein signal transduction GO:0007265 9.76 HRAS JUN KRAS RB1
20 ERBB2 signaling pathway GO:0038128 9.75 HRAS KRAS SRC
21 epidermal growth factor receptor signaling pathway GO:0007173 9.71 FES HRAS KRAS SRC
22 striated muscle cell differentiation GO:0051146 9.67 KRAS RB1
23 positive regulation of DNA biosynthetic process GO:2000573 9.67 PDGFB SRC
24 peptidyl-tyrosine autophosphorylation GO:0038083 9.67 FES LYN SRC YES1
25 regulation of vascular permeability GO:0043114 9.66 SRC YES1
26 regulation of mast cell degranulation GO:0043304 9.66 FES LYN
27 response to isolation stress GO:0035900 9.65 HRAS KRAS
28 myeloid progenitor cell differentiation GO:0002318 9.62 BRAF KIT
29 response to mineralocorticoid GO:0051385 9.59 KRAS SRC
30 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.56 KIT LYN PDGFB SRC
31 ephrin receptor signaling pathway GO:0048013 9.55 HRAS LYN SRC SS18 YES1
32 peptidyl-tyrosine phosphorylation GO:0018108 9.43 FES KIT LYN PDGFB SRC YES1
33 positive regulation of MAP kinase activity GO:0043406 9.02 HRAS KIT KRAS PDGFB SRC
34 positive regulation of transcription by RNA polymerase II GO:0045944 10.18 CREB3L2 FLI1 HRAS JUN RB1 SS18
35 phosphorylation GO:0016310 10.11 BRAF FES KIT LYN SRC YES1
36 positive regulation of transcription, DNA-templated GO:0045893 10.08 CREB3L2 FLI1 JUN PDGFB RB1 SRC
37 intracellular signal transduction GO:0035556 10.05 BRAF KIT LYN SRC SS18
38 positive regulation of cell proliferation GO:0008284 10.04 HRAS JUN KIT KRAS LYN PDGFB
39 protein phosphorylation GO:0006468 10.02 BRAF FES KIT LYN PDGFB SRC

Molecular functions related to Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.88 BRAF FES KIT LYN SRC YES1
2 enzyme binding GO:0019899 9.77 JUN LYN RB1 SRC YES1
3 protein kinase activity GO:0004672 9.63 BRAF FES KIT LYN SRC YES1
4 cAMP response element binding GO:0035497 9.46 CREB3L2 JUN
5 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.43 KIT LYN
6 phosphoprotein binding GO:0051219 9.43 LYN RB1 SRC
7 protein tyrosine kinase activity GO:0004713 9.35 FES KIT LYN SRC YES1
8 non-membrane spanning protein tyrosine kinase activity GO:0004715 8.92 FES LYN SRC YES1
9 protein binding GO:0005515 10.28 ASPSCR1 BRAF EWSR1 FES FLI1 HRAS

Sources for Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....